Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Government agencies communicate via .gov.sg websites (e.g. go.gov.sg/open). Trusted websites
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.

Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

National Drug Formulary

LATA-T LATANOPROST & TIMOLOL EYE DROPS 0.005% & 0.5% W/V [SIN17071P]

Active ingredients: LATA-T LATANOPROST & TIMOLOL EYE DROPS 0.005% & 0.5% W/V

View product's general information
Last updated 24 April 2026

Product Info

LATA-T LATANOPROST & TIMOLOL EYE DROPS 0.005% & 0.5% W/V

[SIN17071P]

Product information

Active Ingredient and Strength

LATANOPROST - 0.005% W/V
TIMOLOL MALEATE EQUIVALENT TO TIMOLOL - 0.5% W/V

Dosage Form

SOLUTION, STERILE

Manufacturer and Country

RAFARM S.A. - GREECE

Registration Number

SIN17071P

Licence Holder

APEX PHARMA MARKETING PTE. LTD.

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

S01ED51

Prescription-only Medicines with Exemptions for Supply without Prescription

NA

Indication

4.1 Therapeutic indications

LATA-T is indicated in adults (including the elderly) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension who are insufficiently responsive to another topical IOP lowering agent.

Dosing

4.2 Posology and method of administration

Posology

Adults (including elderly people)
The recommended dose is one eye drop in the affected eye(s) once a day.

The use of LATA-T may be considered in patients who require both timolol and latanoprost, but it is unknown whether patients who are adequately controlled with timolol given twice daily plus latanoprost given once daily will be as well controlled with LATA-T given once daily. LATA-T should be used for the reduction of intraocular pressure in patients with open angle glaucoma and ocular hypertension who are insufficiently responsive to another intraocular lowering pressure medication.

LATA-T should not be used more than once daily because latanoprost is most effective when given once daily. If there is an insufficient response to LATA-T, then consideration should be given to using the individual agents with timolol dosed twice daily.

If one dose is missed, treatment should continue with the next dose as planned. The dose should not exceed one drop in the affected eye(s) daily.
If more than one topical ophthalmic drug is being used, they should be administered at least five minutes apart.

Contact lenses should be removed before instillation of the eye drops and may be reinserted after fifteen minutes (see section 4.4 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).

When using nasolacrimal occlusion or closing the eyelids for 2 minutes, the systemic absorption is reduced. This may result in a decrease in systemic side effects and an increase in local activity.

Use in children: Safety and effectiveness in children and adolescents have not been established.

Contraindications

4.3 Contraindications

LATA-T is contraindicated in patients with:

  • Reactive airway disease including bronchial asthma, a history of bronchial asthma, or severe chronic obstructive pulmonary disease.

  • Sinus bradycardia, sick sinus syndrome, sino-atrial block, second or third degree atrioventricular block not controlled with pace-maker, overt cardiac failure, or cardiogenic shock.

  • Known hypersensitivity to latanoprost, timolol maleate, or any other component of the product.